GE HealthCare Stock Outlook: Is Wall Street Bullish or Bearish?

Wall Street analysts are generally bullish on GE HealthCare (GEHC), with 11 'Strong Buy' ratings. Argus raised its price target to $110, maintaining a 'Buy' rating. The mean target is $87.87, a 6.8% premium over the current price, and the highest target suggests 33.6% upside.

Original reporting
Published Nov 12, 2026, 5:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GE HealthCare Stock Outlook: Is Wall Street Bullish or Bearish? — source image
Decision brief

The 30-second read

$GEHCBullishMed
01

Why it matters

The upgrade could attract buying interest and support the stock price in the short term.

02

Market read

Analyst target raise is a fresh catalyst for a large‑cap health‑care stock, offering a potential trade idea.

03

What to watch

Potential regulatory or reimbursement risks are not addressed in the target raise.

Relevance 7/10Novelty 7/10Timing: today

Background

The article reports a fresh analyst rating and price‑target update for GE HealthCare.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

Argus raised its price target on GE HealthCare to $110 and kept a Buy rating.

Expected impact

likely upward pressure as investors price in the new $110 target.

Evidence & confidence

The target represents a 33.6% upside from current levels, indicating a material catalyst for the stock.

Market effects

Higher target may lift sentiment in the health‑care equipment sector.

U.S. market focus on large‑cap health‑care stocks could see modest gains.

Limited to investors tracking U.S. health‑care equities.

Counterpoint

Some investors may view the target as overly optimistic given competitive pressures.

Key entities

  • Argus

    Equity research firm that raised the price target.

  • GE HealthCare

    U.S. listed health‑care equipment and services provider.

Related articles

$GEHCMed

GE HealthCare adds new capabilities for Vscan Air ultrasound system

GE HealthCare introduced AI-assisted features AutoAS and Lung Guidance for its Vscan Air handheld ultrasound system, cleared by the FDA and CE. These tools aid clinicians in assessing respiratory and cardiac symptoms. AutoAS estimates aortic stenosis severity, while Lung Guidance provides real-time scanning directions. GE HealthCare reported Q3 revenues of $5.5bn, raising its 2026 outlook.

$GEHCHighAI 8/10

What Sent GE HealthCare Stock Higher?

GE HealthCare Technologies (GEHC) stock rose 6.6% after beating Q3 2026 earnings and revenue estimates, with EPS at $1.34 vs. $1.20 and revenue at $5.51B vs. $5.35B. The company reported 6.2% organic revenue growth and raised its full-year outlook. Management noted profit growth outpaced sales, with an adjusted EBIT margin of 16.6%.

$GEHCHighAI 8/10

GE HealthCare raises 2026 outlook after positive Q3

GE HealthCare reported Q3 revenue of $5.5bn, with 7.2% YoY growth, raising its 2026 earnings outlook to $4.95-$5.05 per share. The company's stock opened at $76, up 7% from $71.11. Pharmaceutical diagnostics (PDx) saw the highest growth at 13% YoY, driven by the acquisition of SOFIE Biosciences for $945m, which is expected to enhance radiopharmaceutical offerings.